Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet’s Disease
Hand-out
Press Releases
Soligenix, Inc.  
November 14, 2024

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet’s Disease

Study DUS-AUBD-01 opens patient enrollment

avatar profile Olean Times Herald

Olean Times Herald


Local & Social